Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gastrointestinal 1Breast 1

Conditions

Mesothelioma 1Lung Neoplasms 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Breast Neoplasms 1

Interventions

Specimen Handling 180Cyclophosphamide 161Magnetic Resonance Spectroscopy 153Biopsy 128Radiotherapy 109Cisplatin 109Bevacizumab 107Carboplatin 101Doxorubicin 96Paclitaxel 94Etoposide 87Filgrastim 81aldesleukin 78Gemcitabine 73Vincristine 72Fluorouracil 72Leucovorin 62fludarabine phosphate 58Docetaxel 58Bortezomib 54Sorafenib 53Cytarabine 51Methotrexate 50Taxes 49Immunoglobulin G 49Disulfides 49Rituximab 48Oxaliplatin 48sargramostim 47Prednisone 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × NIH × Plicamycin × Clear all
NCT01624090 2019-12-30

Mithramycin for Lung, Esophagus, and Other Chest Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
16 enrolled 13 charts
BreastGastrointestinalOther solid neoplasmThoracic

Breast Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Lung Neoplasms, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡